• Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | Morningstar

    المصدر: Buzz FX / 09 مايو 2025 05:36:28   America/Chicago


    Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
    Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for
    Read more...
شارك على،